

Appendix 3Y

Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Antisense Therapeutics Limited (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Robert W Moses
Date of Last Notice:	7 May 2012

Part 1 – Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	a) Direct b) Indirect												
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	b) Spouse												
Date of change	3 rd July 2012												
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">240,000</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">14,833,333</td> <td style="text-align: center;">1,744,370</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">14,833,333</td> <td style="text-align: center;">1,984,370</td> </tr> </tbody> </table>		Shares	Options	Direct	-	240,000	Indirect	14,833,333	1,744,370	Total	14,833,333	1,984,370
	Shares	Options											
Direct	-	240,000											
Indirect	14,833,333	1,744,370											
Total	14,833,333	1,984,370											
Class	a) Ordinary Shares b) Ordinary Shares												
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>a) 240,000</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Indirect</td> <td>b) 1,744,370</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">1,984,370</td> <td style="text-align: center;">-</td> </tr> </tbody> </table>		Shares	Options	Direct	a) 240,000	-	Indirect	b) 1,744,370	-	Total	1,984,370	-
	Shares	Options											
Direct	a) 240,000	-											
Indirect	b) 1,744,370	-											
Total	1,984,370	-											

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Shares	Options
	Direct	a) 240,000
	Indirect	b) 1,744,370
	Total	1,984,370
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) Nil cents per share as per 2008 Employee Option Plan b) 1.1 cents per share	
No. of securities held after change	Shares	Options
	Direct	240,000
	Indirect	16,577,703
	Total	16,817,703
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Options	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

03/07/2012

+ See chapter 19 for defined terms.